Non-small cell lung cancer (NSCLC) is an aggressive disease, with poor prognosis and a high likelihood of brain metastases. Overall survival rates for patients with NSCLC with brain metastases are low. New research coauthored by RTI Health Solutions scientists assessing real-world clinical outcomes in patients with NSCLC with a rare MET exon 14 skipping mutation and brain metastases (mNSCLC) has been published.
The study focused on patients who had received treatment with the MET inhibitor capmatinib, which gained accelerated approval from the US FDA in 2020. To provide context to the results, effectiveness outcomes in capmatinib patients were contrasted with those seen in patients treated with an immunotherapy-containing regimen.
The data for this real-world study were collected from across the US, via a retrospective medical record review, and captured the best overall response rate as well as the duration of response, time-to-treatment discontinuation, disease control rate, and progression-free survival in a routine clinical practice setting. Findings of this study confirm the substantial intracranial efficacy of capmatinib initially reported in the GEOMETRY mono-1 trial.
Because the effectiveness of capmatinib shown in this study is promising in both clinical trial and real-world cohorts, it may indicate a need for early biomarker testing for patients with mNSCLC in order to provide them with appropriately targeted therapies in a timely manner.
See the full publication, including study design and data results, here.